Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 12/20 | 0.37 |
| ▸ | PPARA | Q07869 | 3/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.33 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.33 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.33 |
| ▸ | ITGAV | P06756 | 1/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.33 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.33 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.33 |
| ▸ | ITGAL | P20701 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13995793 | 0.83 | ITGB1 (0.38) | TP53L3MBTL1PPARDFFAR1ITGB3 | |
| SCHEMBL16321478 | 0.81 | TP53 (0.38) | TP53L3MBTL1PPARDPPARAFFAR1 | |
| SCHEMBL4102344 | 0.80 | CYP11B1 (0.39) | POLBTDP1 | |
| SCHEMBL9459051 | 0.76 | TP53 (0.44) | TP53L3MBTL1PPARDPPARAFFAR1 | |
| SCHEMBL8344022 | 0.73 | NPC1 (0.53) | — | |
| SCHEMBL15355707 | 0.73 | NPC1 (0.36) | MAPT | |
| SCHEMBL15355648 | 0.70 | NPC1 (0.43) | POLB | |
| SCHEMBL10780374 | 0.69 | AKR1C4 (0.35) | PPARDFFAR1AKR1C4AKR1C3AKR1C2 | |
| SCHEMBL7414654 | 0.69 | L3MBTL1 (0.44) | TP53L3MBTL1PPARDFFAR1DGAT1 | |
| SCHEMBL3592207 | 0.68 | TP53 (0.39) | TP53L3MBTL1FFAR1ITGB3ITGB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1656141-B1 | TREATMENT FOR ALZHEIMER S DISEASE AND RELATED CONDITIONS | MERCK SHARP & DOHME (GB) | 2010-04-14 | — | — | EP | disclosed |
| US-20090118157-A1 | Processes For Production Of Wine Lactone And Its Intermediates And Application Of The Lactone | SAN-EI GEN F.F.I. INC. (JP) | 2009-05-07 | — | — | US | disclosed |
| US-20080153817-A1 | Treatment for Alzheimer's Disease and Related Conditions | MERCK SHARP & DOHME LTD. (GB) | 2008-06-26 | — | — | US | disclosed |
| EP-1656141-A1 | TREATMENT FOR ALZHEIMER S DISEASE AND RELATED CONDITIONS | MERCK SHARP & DOHME LTD. (GB) | 2006-05-17 | — | — | EP | disclosed |
| WO-2005013985-A1 | TREATMENT FOR ALZHEIMER'S DISEASE AND RELATED CONDITIONS | MERCK SHARP & DOHME LIMITED (GB) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153817-A1 | Treatment for Alzheimer's Disease and Related Conditions | PSEN1, PSEN2, APP | TP53 3990/4885L3MBTL1 4244/4885PPARD 1278/4885 |
| US-20090118157-A1 | Processes For Production Of Wine Lactone And Its Intermediates And Application Of The Lactone | DCXR, COASY, AKR7A2 | TP53 538/4885L3MBTL1 2571/4885PPARD 2585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.